- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06274983
DMD- Interactive Virtual Reality Study (DMD-IVR)
Investigating the Viability and Acceptability of an Interactive Virtual Reality (IVR) System on Physiotherapy Rehabilitation in Paediatric Duchenne Muscular Dystrophy (DMD) Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Duchenne Muscular Dystrophy (DMD) is a genetic disease causing muscle weakness and wasting affecting 2,500 people in the UK. International Standards of Care recommend that children with DMD undertake a daily stretching programme to maintain maximum muscle extensibility and optimise function. A lot of children are not motivated to perform these exercises, leading to earlier complications, reduced function and a poorer long-term prognosis.
Our collaborative research group has previously developed an interactive Immersive Virtual Reality (IVR) system to improve the delivery, engagement and success of physiotherapy for adult amputees, burns' patients and children with upper limb injuries. VR headsets have become more accessible in terms of price, usability and portability.
In a recent PPI survey, 78% of paediatric DMD patients stated that a VR system could improve physiotherapy engagement and performance. This study will investigate the feasibility and acceptability of an IVR device on paediatric DMD rehabilitation.
In phase 1 of this study, clinicians, physiotherapists, parents, carers and patients will participate in a co-design workshop to explore core VR rehabilitation scenarios. An IVR platform will be developed that will emulate current DMD physiotherapy. In phase 2, investigators will ask therapists and children to take part in testing the IVR platform. VR scenarios will be further developed and then tested in a trial with 16 DMD patients aged 5-10 years.
Pre and post-trial assessments will be performed to determine the effect of the IVR system on improving physiotherapy adherence, muscle strength testing, quality of life and anxiety. Qualitative interviews and questionnaires will be conducted with patients and clinical staff to obtain feedback on patient acceptability as well as practicality and acceptability of using IVR in a clinical setting.
This study will help determine if an IVR system can improve the physiotherapy of young patients with DMD.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
South Yorkshire
-
Sheffield, South Yorkshire, United Kingdom, S10 2TH
- Sheffield Childrens NHS FT
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged 5-10 years
- Diagnosed with Duchenne muscular dystrophy (DMD) and receiving lower limb physiotherapy care
- Ambulant patients
- Able to speak/understand English
Exclusion Criteria:
- Physical or cognitive difficulties indicating the child would struggle to use the device or complete study activities.
- Outside age range.
- Non-ambulant patients.
- Facial injuries precluding the use of HMD.
- Issues relating to balance that could be affected by VR.
- Severe visual impairment.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: IVR platform trial
8 DMD patients from Sheffield Children's Hospital and 8 DMD patients from Leeds Teaching Hospital to trial the IVR platform.
|
8 DMD patients from Sheffield Children's Hospital and 8 DMD patients from Leeds Teaching Hospital to trial the IVR platform.
Patients will receive device training and then use the VR device at home for 12 weeks.
Physiotherapists will conduct pre (visit 1) and post (visit 2) assessments to assess changes using a Goniometer (measures ankle range of movement), PEDSQL quality of life data, GAD-7 anxiety questions and the NorthStar Ambulatory Assessment.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Compliance: Ratings of frequency of the DMD-IVR device use for the participant's to complete recommended physiotherapy exercises.
Time Frame: 8 weeks
|
The physiotherapy team prescribe a defined frequency for use individualised for each child. Pre and Post Home diary: Families will be asked to complete a paper/electronic diary to capture compliance with current physio regime (including frequency of stretching and other activities for a 4 week 'pre intervention' period). The system will log the frequency of use of the DMD-VR platform during the 8 weeks (quantitative) which will be cross referenced with the patient completed activity diary. |
8 weeks
|
|
Compliance: Ratings of duration of the DMD-IVR device use for the participant's to complete recommended physiotherapy exercises.
Time Frame: 8 weeks
|
The physiotherapy team prescribe a defined time for use individualised for each child. Pre and Post Home diary: Families will be asked to complete a paper/electronic diary to capture compliance with current physio regime (including duration of stretching and other activities for a 4 week 'pre intervention' period). The system will log the duration of use of the DMD-VR platform during the 8 weeks (quantitative) which will be cross referenced with the patient completed activity diary. |
8 weeks
|
|
Post-trial qualitative interviews on perceptions, acceptability, usability and effectiveness of DMD-IVR device in the context of the family's overall burden of care
Time Frame: 30 minutes
|
A semi-structured interview will be conducted by the research nurse in person/phone with the patient and parent after the DMD-IVR rehabilitation at home trial (8 week). Open-ended questions provided qualitative data relating to acceptability, practicality, difficulty, pain and enjoyability, and participant attitudes towards the IVR system and its future deployment. Another semi-structured interview was conducted with the clinical staff by the researcher in person at the end of the trial to explore her attitudes towards the DMD-IVR device and future deployment (8 week). Both interviews were recorded, transcribed and anonymised. |
30 minutes
|
|
DMD-IVR Effectiveness standard functional assessments: North Star Ambulatory Assessment (NSAA)
Time Frame: 10 minutes
|
NSAA is a 17-item rating scale used to measure functional motor abilities in ambulant children with DMD. The test must be completed without the use of any thoracic brace or leg orthoses. Therapist asks the patient to complete activities listed below. The activities are graded as follows: 2 - "Normal" - no obvious modification of activity 1 - Modified method but achieves goal independent of physical assistance from another 0 - Unable to achieve independently This scale is ordinal with 34 as the maximum score indicating fully-independent function. Several studies have shown that NSAA is a quick, specific, reliable, valid, and clinically relevant method to measure the functional motor ability of ambulant children with DMD. NSAA is considered to be suitable to be used in research and in a multicentric setting provided that adequate training is given. [https://www.physio-pedia.com/North_Star_Ambulatory_Assessment] Evaluation at the baseline |
10 minutes
|
|
DMD-IVR effectiveness measures with a Timed test 4 stair climb
Time Frame: 10 minutes
|
Evaluation at the baseline screening visit by the physiotherapist and at the end of the study (week 8).
|
10 minutes
|
|
DMD-IVR effectiveness measured joint range of movement using Goniometer (Standard BASELINE® 12-inch)
Time Frame: 10 minutes
|
Goniometer device (Standard BASELINE® 12-inch plastic goniometer, (Model 12- 1000-Fabrication Enter- prises, Inc: White Plains, New York) will be use by the clinical staff before and after the patient's rehabilitation to document the initial and subsequent range of motion, evaluate their progress and to determine the level of disability.
Clinical staff used the goniometer.
To assess any changes in range of movement using goniometer measured ankle range of movement, plus any other joint range of movement physiotherapist deemed clinically valuable.
The clinical team examined the differences between a range of movements join (flexion, extension, abduction, and adduction) before and after the VR rehabilitation.
The greater the range of movement the better.
Evaluation at the baseline screening visit by the physiotherapist and at the end of the study (week 8).
|
10 minutes
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- SCH-2629
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Duchenne Muscular Dystrophy
-
Dyne TherapeuticsRecruitingMuscular Dystrophies | Muscular Dystrophy, Duchenne | Duchenne Muscular Dystrophy (DMD) | Muscular Dystrophy, Duchenne and Becker Types | Genetic Disease, X-Linked | Genetic Disease, Inborn | DMD | Congenital, Hereditary, and Neonatal Diseases and Abnormalities | Muscular Dystrophy (DMD) | Muscular Dystrophies... and other conditionsUnited States
-
Cairo UniversityCompletedMuscular Dystrophy, Duchenne TypeEgypt
-
Chaitanya Hospital, PuneUnknownMuscular Dystrophy | Duchenne Muscular Dystrophy,India
-
Medical University of GdanskRecruitingDuchenne Muscular Dystrophy (DMD)Poland
-
PepGen IncWithdrawnDuchenne Muscular Dystrophy (DMD)United Kingdom
-
ItalfarmacoCompletedDuchenne Muscular Dystrophy (DMD)Italy
-
Santhera PharmaceuticalsTerminatedDuchenne Muscular Dystrophy (DMD)United States, Spain, Netherlands, Sweden, Germany, France, Belgium, United Kingdom, Italy, Ireland, Switzerland, Austria, Bulgaria, Hungary, Israel
-
Sarepta Therapeutics, Inc.CompletedDuchenne Muscular Dystrophy (DMD)United States
-
Hospital RudolfstiftungOesterreichische MuskelforschungCompletedCarrier of Duchenne Muscular DystrophyAustria
-
General Hospital of Chinese Armed Police ForcesUnknownDuchenne Muscular Dystrophy (DMD)China
Clinical Trials on IVR platform trial
-
Consumer Wellness SolutionsIndiana University School of MedicineCompleted
-
Auritec PharmaceuticalsEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedHuman Immunodeficiency Virus (HIV) ProphylaxisUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedHIV InfectionsUnited States
-
Icahn School of Medicine at Mount SinaiCompletedImmersive Virtual Reality for Chronic Neuropathic Pain After Spinal Cord Injury: A Feasibility TrialChronic Pain | Neuralgia | Spinal Cord InjuriesUnited States
-
University of Alabama at BirminghamUS Department of Veterans Affairs; University of California, San Francisco; University...CompletedChronic Obstructive Pulmonary Disease | Congestive Heart FailureUnited States
-
Virginia Polytechnic Institute and State UniversityNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); Carilion... and other collaboratorsCompletedDiabetes PreventionUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
University of MaltaEnrolling by invitationCoronary Artery Bypass | Cardiac DiseaseMalta
-
Harvard School of Public Health (HSPH)National Cancer Institute (NCI)CompletedCervical Cancer | Breast Cancer | Colorectal CancerUnited States
-
Johns Hopkins Bloomberg School of Public HealthInstitute of Epidemiology, Disease Control and ResearchCompletedSurveys and Questionnaires | Non Communicable DiseasesBangladesh